Joel Greenblatt Bluebird Bio, Inc. Transaction History

Gotham Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $66,643 - $98,059	11,550 New	11,550 $79,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $287,462 - $453,616	-4,864 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $95,702 - $126,536	-1,077 Reduced 18.13%	4,864 $710,000
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $110,899 - $142,007	-1,113 Reduced 15.78%	5,941 $932,000
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $4,020 - $5,735	-38 Reduced 0.54%	7,054 $1.2 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $4.26 Million - $6.86 Million	-52,460 Reduced 88.09%	7,092 $1.26 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $3.44 Million - $5.44 Million	59,552	59,552 $8.18 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.